ELN-DAVID is the international working group for MRD ASSESSMENT and VALIDATION in AML and is part of the European LeukemiaNet (ELN).
The objective of ELN-DAVID is to promote measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) and related diseases through:
All diagnostic laboratory MRD techniques are subject to evaluation and standardization by ELN-DAVID including, but not limited to quantitative polymerase chain reaction (qPCR), multicolor flow cytometry (MFC), next-generation sequencing (NGS) and digital PCR (dPCR).
Structure and Management
ELN-DAVID is governed by the executive board. The executive board consists of the chair, the vice-chair, the treasurer and subcommittee chairs for flow-, qPCR- and NGS-MRD, and the clinical subcommittee.
All members are approved by the executive board. The advisory board members and patient representatives are appointed by the executive board. Members, advisory board and patient representatives participate in the general assembly and elect the executive board members. The period of office of the members of the Board is three years.
The executive board may appoint administrative directors who legally represent ELN-DAVID in the participating countries.
- New members may apply for admission to ELN-DAVID in writing or orally to the chair of ELN-DAVID .
- The application should be supported by a letter of recommendation from a full member of ELN-DAVID and/or by proof of a publication on MRD in AML as first or last author.
- The executive board of ELN-DAVID decides on the admission of new members.